Navigation Links
Transposagen Announces Exclusive License with Charles River Laboratories for p53 and Bcrp TGEM™ Knockout Rat Models
Date:10/13/2010

harmaceuticals, a leader in the creation of genetically modified rat models.  Knockout rat models are a new and emerging tool in drug discovery and development, and Transposagen's p53 and Bcrp TGEM™ Knockout Rat Models are expected to quickly become widely accepted for research in oncology and other therapeutic areas."  

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc., a Lexington, KY based company, is the worldwide leader in the creation of unique genetically modified rat models.  The company's signature products, TKO™ Knockout Rat Models and TGEM™ Rat Models, mimic human diseases and are used for drug discovery and development research. The company also creates custom transgenic rat models to customer specifications. For more information or to request a custom rat model, visit www.transposagenbio.com.Contact:Jack Crawford145 Graham Ave.ASTeCC Bldg., Suite A217Lexington, KY 40506859-428-8561
'/>"/>

SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MKS Instruments Announces Third Quarter 2010 Earnings Conference Call
2. OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
3. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
4. Boston Scientific Announces Global Launch of Journey™ Guidewire
5. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
6. CORRECTED - Akorn, Inc. Announces Date Change for Third Quarter 2010 Earnings Release and Conference Call
7. Prime Therapeutics Announces URAC Accreditation
8. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
9. Cellectis bioresearch Announces Establishment of Subsidiary in the US
10. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
11. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, ... Tobago Ministry of Health approved the introduction of ... increases the cure rate from Hepatitis C, and ... genotype 1 virus. Telaprevir is available in ... INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... 25, 2014  Acsis Inc., the market leader ... solutions, has recently posted an article, "Future ... and future needs for companies, extended supply chain, ... chain model no longer work today.  The article ... growth of mobile technology, machine to machine (M2M) ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
(Date:7/27/2014)... July 27, 2014 The European Agricultural ... in Europe with analysis and forecast of revenue. The ... from around $509.4 million in 2013 to $657.1 million ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. It also provides a ...
(Date:7/27/2014)... 27, 2014 Metachromatic leukodystrophy (MLD, ... storage disease which is commonly listed in the ... sphingolipidoses as it affects the metabolism of sphingolipids. ... the fatty covering which acts as an insulator ... nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 One of the ... genomics products from the Asia Pacific (APAC) region. The Diagnostics ... to generate high demand for genomics solutions, thereby contributing to ... will grow at a CAGR of 11.21 percent over ... driver of the market is an increase in the demand ...
(Date:7/27/2014)... 2014 Alta Resources , a ... for Fortune 500 brands, announced today that it plans ... in Wisconsin, California, Florida and the Philippines. , A ... clients, which have seasonal ramp-ups that require additional staffing ... 2014 through February 2015. As more consumers become eligible ...
(Date:7/27/2014)... 27, 2014 Wright & Schulte LLC ... filed a GranuFlo lawsuit against Fresenius Medical Care ... over the recalled dialysis drugs GranuFlo and NaturaLyte. The ... by not disclosing the heart attack risks associated with ... Fresenius notified its own clinics, practitioners and physicians about ...
Breaking Medicine News(10 mins):Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 2Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 3Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 4Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 5Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 2Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 4Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 5
... of Chemicals, has shifted the burden or responsibility of handling ... would be bound by law to make use of only ... law aims to make chemicals used in all products ; ... ,The European Parliament has approved this legislation on ...
... plausible culprit for rendering sick nearly 260 Tewksbury students, ... stomach virus// has allegedly gripped several of the students ... not about to spare anyone- teachers, parents and siblings ... us to keep everything clean,” said Sue McLaughlin, co-chairwoman ...
... for ovarian cancer are at increased risk of a ... have high// levels of a binding protein that triggers ... of malignancy. ,“Now there’s the possibility that ... surgery might identify women most at risk for recurrence ...
... symptoms, including enlarged or painful breast tissue, but the ... Mayo Clinic Cancer Center. // Mammograms are used to ... very rare in males. ,Their study, presented Saturday, ... Antonio Breast Cancer Symposium, suggests physicians should reconsider ordering ...
... vaccine against HIV/AIDS, the 'social vaccine' of mass awareness needs ... a top UN official here said Saturday. // ... HIV/AIDS," said Peter Piot, executive director of United Nations Programme ... create a mass awareness to educate the people about the ...
... followed the discovery of neural stem cells and their potential ... spinal cord//, recent research identified “cancer stem cells,” a small ... cells comprising a malignant brain tumor. Theoretically, if these mother ... to sustain itself. On the other hand, if these cells ...
Cached Medicine News:Health News:'Clumping' Protein Linked to Return of Ovarian Cancer 2Health News:Use of Mammograms in Men 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 3
... 80 mm. Grooved buckle. Size: 2.3 x 4.0 ... original Scleral Sponge II line designed by Harvey ... closed cell sponge which is non-toxic and non-antigenic. ... scleral intrusion. These implants are packaged sterile and ...
For use with E5381 700 Circling Band (240 style)....
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 12.0 mm....
For use with E5381 600 Circling Band (40 style)....
Medicine Products: